Skip to main content
Create Account
About PLI PLUS
Help
Contact Us
Questions? Comments?
Contact us.
Email:
PLUS@pli.edu
Phone:
877.900.5291
PLI.edu
SIGN IN
Search
Browse
All Content
Books
- Answer Books
- Course Handbooks
- Journals
- Treatises
Forms
Transcripts
My Bookshelf
My History
< Back To Results
1 in 1 results
Previous Result
Next Result
Advanced Patent Prosecution Workshop 2018: Claim Drafting & Amendment Writing
Practice Area:
Intellectual Property
Published:
Jul 2018
ISBN:
9781402432019
PLI Item #:
219235
CHB Spine #:
G1378
Terms & Connectors
Natural Language
Email
Print
Add To Bookshelf
Permalink
Table of Contents
Related Items
Select All
Front Matter
Faculty Bios
Table of Contents
Chapter 1. Conflicts of Interest in Patent Acquisition and Patent Litigation Representation (April 28, 2016)
Chapter 2. Prosecution Ethics, Including Therasense v. Becton Dickinson (April 28, 2016)
Chapter 3. Supplemental Examination
Chapter 4. Specification Drafting: The Story Behind the Invention—Biotechnology Edition (May 1, 2018)
Chapter 5. Specification Drafting for the Chemical/Pharmaceutical Patent Application
Chapter 6. The Great Specification Balancing Act
Chapter 7. Drafting the Specification
Chapter 8. Antibody Claim Drafting: Reaching the End of the “Antibody Exception”
Chapter 9. Advanced Claim Drafting Issues for Biotechnology Patent Applications
Chapter 10. Chemical and Pharmaceutical Claim Drafting 2018
Chapter 11. Chemical and Pharmaceutical Claim Drafting 2018 (PowerPoint slides)
Chapter 12. ElectroMechanical Arts Claim under Section § 101 of the Patent Act (April 28, 2016)
Chapter 13. § 112 (f) and the Current Status of “Means for”, “Step for” and “Nonce” Word Claim Elements (April 28, 2016)
Chapter 14. The Winning Mechanical Claim (April 28, 2016)
Chapter 15. Techniques for Responding to Obviousness Rejections (2018)
Chapter 16. Ann M. McCrackin, Steven W. Lundberg and Gregory M. Stark, Crafting the Claims
Chapter 17. WebEx Interviews at the USPTO
Chapter 18. United States Patent and Trademark Office, Interview Specialist List
Chapter 19. Timothy Callahan, United States Patent and Trademark Office, Face-to-Face Examiner Interviews: A Demonstration of USPTO Tools
Chapter 20. Post-Grant Proceedings at the USPTO: Prefiling Considerations and Effectively Defending Against a Petition, Excerpts from Chapters 2–5 of the PLI Publication, Post-Grant Proceedings Before the Patent Trial and Appeal Board (October 2016)
Chapter 21. Claim Drafting for Biotechnology Patent Applications
Chapter 22. Update on Patent Agent Privilege
Chapter 23. The Use of “Means Plus Function” Language in Patent Claims
Chapter 24. The Use of “Means Plus Function” Language in Patent Claims (PowerPoint slides)
Chapter 25. Responding to the “Difficult” Obviousness Rejection
Chapter 26. Claiming Strategies for Fintech and Business Methods: Plan Ahead for Patent Eligibility Rejections (April 16, 2018)
Chapter 27. Conducting Interviews at the U.S. Patent and Trademark Office
Chapter 28. United States Patent and Trademark Office, Interview Best Practices
Chapter 29. United States Patent and Trademark Office, Interview Practice Training Summary: Effective Interview Practice
Chapter 30. Patent Term Adjustment and Recent Legal Developments
Chapter 31. Ethics Issues for Patent Prosecutors
Chapter 32. The New Section 102—Exploring the Changes
Chapter 33. Article of Manufacture Claims for Computer Related Inventions
Chapter 34. Advanced Claim Drafting Issues (PowerPoint slides)
Chapter 35. Advanced Claim Drafting Issues (Personalized/Precision Medicine) (May 4, 2018)
Chapter 36. Advanced Claim Drafting Issues (Personalized/Precision Medicine) (PowerPoint slides)
Chapter 37. Subject Matter Eligibility in the Life Sciences (Especially in View of Language)
Chapter 38. Responding to the Obviousness Rejection
Chapter 39. Overcoming Obviousness Rejections under 35 U.S.C. §103
Chapter 40. Advanced Issues in Patent Specification Drafting
Chapter 41. Unpacking the Written Description Requirement
Chapter 42. Amgen Inc., Amgen Manufacturing Limited, Amgen USA, Inc. v. Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S., LLC, No. 2017-1480 (Fed. Cir. Oct. 5, 2017)
Chapter 43. What a Litigator Hates to See in the Prosecution History of a Patent
Chapter 44. What a Litigator Hates to See in the Prosecution History of a Patent (PowerPoint slides)
Index
About Us
